Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients September 22, 2021 • 8:00 AM EDT
Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma August 17, 2021 • 8:00 AM EDT
Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021 August 12, 2021 • 8:00 AM EDT
Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021 August 4, 2021 • 8:00 AM EDT
Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM July 1, 2021 • 8:00 AM EDT
Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors June 3, 2021 • 8:00 AM EDT
Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021 June 2, 2021 • 8:00 AM EDT
Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma May 26, 2021 • 8:00 AM EDT
Kintara Therapeutics Announces Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update May 14, 2021 • 8:00 AM EDT